Immunomedics Stock Price, News & Analysis (NASDAQ:IMMU)

$12.12 -0.23 (-1.86 %)
(As of 12/13/2017 02:15 AM ET)
Previous Close$12.35
Today's Range$11.82 - $12.79
52-Week Range$3.30 - $14.48
Volume3.03 million shs
Average Volume3.15 million shs
Market Capitalization$1.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Debt-to-Equity Ratio-0.29%
Current Ratio0.74%
Quick Ratio0.74%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million
Price / Sales596.27
Cash FlowN/A
Price / CashN/A
Book Value($0.54) per share
Price / Book-22.44

Profitability

Trailing EPS($2.23)
Net Income$-153,200,000.00
Net Margins-8,412.93%
Return on EquityN/A
Return on Assets-83.13%

Miscellaneous

Employees138
Outstanding Shares152,020,000

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings results on Thursday, February, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03. The biopharmaceutical company earned $0.38 million during the quarter, compared to analyst estimates of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 brokerages have issued 1-year target prices for Immunomedics' shares. Their forecasts range from $15.00 to $16.00. On average, they expect Immunomedics' share price to reach $15.50 in the next twelve months. View Analyst Ratings for Immunomedics.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Behzad Aghazadeh Ph.D., Independent Chairman of the Board (Age 46)
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance (Age 59)
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director (Age 79)
  • Brendan Delaney, Chief Commercial Officer
  • Cynthia L. Sullivan, Director (Age 61)
  • Scott A. Canute, Independent Director (Age 57)
  • Peter Barton Hutt, Independent Director (Age 82)
  • Khalid Islam Ph.D., Independent Director (Age 61)
  • Brian A. Markison, Lead Independent Director (Age 58)

Who owns Immunomedics stock?

Immunomedics' stock is owned by many different of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (6.58%), NEA Management Company LLC (1.83%), Jennison Associates LLC (1.20%), Pictet Asset Management Ltd. (0.99%), Bank of New York Mellon Corp (0.45%) and Iguana Healthcare Management LLC (0.33%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, EAM Investors LLC, 683 Capital Management LLC, Sphera Funds Management LTD., Wells Fargo & Company MN, Allianz Asset Management GmbH, Candriam Luxembourg S.C.A. and Public Employees Retirement Association of Colorado. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Pictet Asset Management Ltd., Jennison Associates LLC, Nicholas Investment Partners LP, Schwab Charles Investment Management Inc., Lyon Street Capital LLC, Chicago Equity Partners LLC and Bank of New York Mellon Corp. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $12.12.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $1.89 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immunomedics (NASDAQ:IMMU) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.50$15.50$13.00$9.00
Price Target Upside: 32.93% upside32.93% upside62.91% upside9.36% upside

Immunomedics (NASDAQ:IMMU) Consensus Price Target History

Price Target History for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Jefferies GroupBoost Price TargetBuy$14.00 -> $16.00N/AView Rating Details
7/24/2017CowenReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Immunomedics (NASDAQ:IMMU) Earnings Estimates

2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 76.32%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2017Brian A MarkisonDirectorSell8,390$11.89$99,757.10View SEC Filing  
11/15/2017Behzad AghazadehInsiderBuy1,325,000$10.47$13,872,750.00View SEC Filing  
11/14/2017Venbio Select Advisor LlcDirectorBuy1,150,000$10.39$11,948,500.00View SEC Filing  
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immunomedics (NASDAQ IMMU) News Headlines

Source:
DateHeadline
ETFs with exposure to Immunomedics, Inc. : December 11, 2017ETFs with exposure to Immunomedics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:25 PM
Immunomedics (IMMU) & Its Peers Head to Head ReviewImmunomedics (IMMU) & Its Peers Head to Head Review
www.americanbankingnews.com - December 10 at 5:20 PM
Immunomedics' Data Is Good News for Seattle Genetics, TooImmunomedics' Data Is Good News for Seattle Genetics, Too
finance.yahoo.com - December 8 at 9:10 AM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017
finance.yahoo.com - December 8 at 9:10 AM
Immunomedics (IMMU) Updated Results With Sacituzumab Govitecan In Patients With Relapsed Or Refractory mTNBCImmunomedics (IMMU) Updated Results With Sacituzumab Govitecan In Patients With Relapsed Or Refractory mTNBC
www.streetinsider.com - December 7 at 3:29 PM
Why Immunomedics, Inc. Is Soaring Today - Motley FoolWhy Immunomedics, Inc. Is Soaring Today - Motley Fool
www.fool.com - December 7 at 9:08 AM
Today’s Research Reports on Stocks to Watch: Immunomedics and Valeant PharmaceuticalsToday’s Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals
finance.yahoo.com - December 7 at 9:08 AM
Why Immunomedics, Inc. Is Soaring TodayWhy Immunomedics, Inc. Is Soaring Today
finance.yahoo.com - December 7 at 9:08 AM
Immunomedics rallies 17% ahead of data release on lead candidate IMMU-132Immunomedics rallies 17% ahead of data release on lead candidate IMMU-132
seekingalpha.com - December 6 at 12:23 PM
Immunomedics (IMMU) Rating Lowered to Sell at ValuEngineImmunomedics (IMMU) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 9:38 PM
Jim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics - BenzingaJim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics - Benzinga
www.benzinga.com - December 1 at 11:46 AM
ETFs with exposure to Immunomedics, Inc. : November 30, 2017ETFs with exposure to Immunomedics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:27 PM
Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:09 AM
Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18
finance.yahoo.com - November 28 at 9:33 AM
Immunomedics, Inc. (IMMU) Given Average Rating of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 12:34 PM
Immunomedics, Inc. (IMMU) Stock Rating Lowered by Zacks Investment ResearchImmunomedics, Inc. (IMMU) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:32 AM
Immunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 SharesImmunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 Shares
www.americanbankingnews.com - November 21 at 9:10 PM
Immunomedics (IMMU) Jumps: Stock Rises 5.4%Immunomedics (IMMU) Jumps: Stock Rises 5.4%
finance.yahoo.com - November 17 at 6:32 AM
Options Traders Expect Huge Moves in Immunomedics (IMMU) StockOptions Traders Expect Huge Moves in Immunomedics (IMMU) Stock
finance.yahoo.com - November 17 at 6:32 AM
Venbio Select Advisor Llc Acquires 1,150,000 Shares of Immunomedics, Inc. (IMMU) StockVenbio Select Advisor Llc Acquires 1,150,000 Shares of Immunomedics, Inc. (IMMU) Stock
www.americanbankingnews.com - November 16 at 4:22 PM
Insider Buying: Immunomedics, Inc. (IMMU) Insider Purchases 1,325,000 Shares of StockInsider Buying: Immunomedics, Inc. (IMMU) Insider Purchases 1,325,000 Shares of Stock
www.americanbankingnews.com - November 15 at 7:31 PM
Wells defends Immunomedics, 19% selloff a "buying opportunity" - Seeking AlphaWells defends Immunomedics, 19% selloff a "buying opportunity" - Seeking Alpha
seekingalpha.com - November 15 at 2:55 AM
Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium - GlobeNewswire (press release)Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium - GlobeNewswire (press release)
globenewswire.com - November 15 at 2:55 AM
Immunomedics Emerges With New Leadership - Seeking AlphaImmunomedics Emerges With New Leadership - Seeking Alpha
seekingalpha.com - November 15 at 2:55 AM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017
finance.yahoo.com - November 13 at 7:54 PM
Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer SymposiumImmunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - November 13 at 7:54 PM
44 Biggest Movers From Friday - Benzinga44 Biggest Movers From Friday - Benzinga
www.benzinga.com - November 13 at 6:21 AM
Immunomedics, Inc. (IMMU) Short Interest UpdateImmunomedics, Inc. (IMMU) Short Interest Update
www.americanbankingnews.com - November 12 at 1:32 AM
Immunomedics (IMMU) Appoints Michael Pehl as President and CEOImmunomedics (IMMU) Appoints Michael Pehl as President and CEO
www.streetinsider.com - November 11 at 12:11 PM
Investor Network: Immunomedics, Inc. to Host Earnings CallInvestor Network: Immunomedics, Inc. to Host Earnings Call
www.finanznachrichten.de - November 11 at 12:11 PM
BRIEF-Immunomedics appoints Michael Pehl president and CEOBRIEF-Immunomedics appoints Michael Pehl president and CEO
www.reuters.com - November 11 at 12:11 PM
Immunomedics, Inc. to Host Earnings CallImmunomedics, Inc. to Host Earnings Call
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative GrowthImmunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate UpdateImmunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics reports 1Q lossImmunomedics reports 1Q loss
finance.yahoo.com - November 11 at 12:10 PM
Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMTEdited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017
finance.yahoo.com - November 3 at 9:46 AM
Comparing Immunomedics (IMMU) and Oramed Pharmaceuticals (ORMP)Comparing Immunomedics (IMMU) and Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - November 1 at 1:22 AM
ETFs with exposure to Immunomedics, Inc. : October 31, 2017ETFs with exposure to Immunomedics, Inc. : October 31, 2017
finance.yahoo.com - October 31 at 10:23 PM
Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : October 31, 2017Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : October 31, 2017
finance.yahoo.com - October 31 at 10:23 PM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017
finance.yahoo.com - October 30 at 10:06 PM
Interesting IMMU Put And Call Options For December 15thInteresting IMMU Put And Call Options For December 15th
www.thestreet.com - October 25 at 6:27 AM
Technical Insights on Biotech Stocks -- Conatus Pharma ... - PR Newswire (press release)Technical Insights on Biotech Stocks -- Conatus Pharma ... - PR Newswire (press release)
www.prnewswire.com - October 18 at 1:14 AM
Immunomedics, Inc. (IMMU) Sees Large Decline in Short InterestImmunomedics, Inc. (IMMU) Sees Large Decline in Short Interest
www.americanbankingnews.com - October 13 at 1:32 AM
Immunomedics, Inc. (IMMU) PT Raised to $16.00 at Jefferies Group LLCImmunomedics, Inc. (IMMU) PT Raised to $16.00 at Jefferies Group LLC
www.americanbankingnews.com - October 9 at 8:58 PM
Financial Comparison: Intrexon Corporation (XON) & Immunomedics (IMMU)Financial Comparison: Intrexon Corporation (XON) & Immunomedics (IMMU)
www.americanbankingnews.com - October 8 at 4:24 PM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 8 at 12:50 PM
Immunomedics Reaches Analyst Target PriceImmunomedics Reaches Analyst Target Price
www.nasdaq.com - October 5 at 9:50 PM
Immunomedics, Inc. (IMMU) Stock Rating Upgraded by Zacks Investment ResearchImmunomedics, Inc. (IMMU) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 4 at 11:10 PM
ETFs with exposure to Immunomedics, Inc. : October 3, 2017ETFs with exposure to Immunomedics, Inc. : October 3, 2017
finance.yahoo.com - October 4 at 5:22 PM

SEC Filings

Immunomedics (NASDAQ:IMMU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immunomedics (NASDAQ IMMU) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.